Apotex Inc. freed both itself and its employees from the US Department of Justice's probe of the generics industry under a three-year deferred prosecution agreement to resolve the DOJ's charge that it fixed the price of the cholesterol medication pravastatin.
Under the agreement, announced on 7 May, Apotex admitted that it conspired with other generic drug sellers to artificially...







